公开(公告)号：US20180044399A1

公开(公告)日：2018-02-15

申请号：US15525906

申请日：2015-11-09

Applicant: RINAT NEUROSCIENCE CORP. ,  CELLECTIS

Inventor： Arvind RAJPAL ,  Shobha Chowdary POTLURI ,  Laurent POIROT ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Donna Marie STONE ,  Barbra Johnson SASU

IPC: C07K14/705 ,  C07K14/725 ,  A61K35/17 ,  C07K16/28 ,  C12N5/0783

CPC classification number: C07K14/70503 ,  A61K35/17 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/3069 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or

公开(公告)号：US20170360835A1

公开(公告)日：2017-12-21

申请号：US15659792

申请日：2017-07-26

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20170035866A1

公开(公告)日：2017-02-09

申请号：US15302913

申请日：2015-04-10

Applicant: CELLECTIS

Inventor： Laurent POIROT ,  Mathieu SIMON

IPC: A61K39/00 ,  C07K14/725 ,  C12N9/12

Abstract: The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.

Abstract translation: 本发明涉及工程改造的免疫细胞，其制备方法及其用作药物，特别是用于免疫治疗。 本发明的工程化免疫细胞的特征在于，选自编码GCN2的基因和编码PRDM1的基因的至少一种基因被灭活或抑制。 这种修饰的免疫细胞对由例如肿瘤细胞引起的精氨酸和/或色氨酸消耗的微环境具有抗性，这使得本发明的免疫细胞特别适用于免疫治疗。 本发明开启了使用免疫细胞治疗不同类型恶性肿瘤的标准和负担得起的过继免疫治疗策略的方法。

公开(公告)号：US20160272999A1

公开(公告)日：2016-09-22

申请号：US14892934

申请日：2014-04-01

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85

CPC classification number: C12N15/85 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N9/22 ,  C12N2510/00

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

Abstract translation: 本发明涉及开发用于免疫治疗的遗传工程化，优选非同种异体反应性T细胞的方法。 该方法涉及使用RNA引导的核酸内切酶，特别是Cas9 / CRISPR系统，以特异性靶向T细胞中关键基因的选择。 工程化T细胞还旨在表达嵌合抗原受体（CAR）以将其免疫活性重定向于恶性或感染细胞。 本发明开启了使用T细胞治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。